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candidate genes was then compared 
to a list of genes that are located in 
regions of copy number gain in colon 
cancer, allowing the identification of 
cyclin-dependent kinase 8 (CDK8) as a 
new colon cancer oncogene (Firestein 
et al., 2008). The efforts of Firestein et 
al. and Zender et al. highlight the power 
of combining loss-of-function genetic 
screens with analysis of copy num-
ber alterations found in human cancer. 
That only one of the six genes studied 
in detail by Zender et al. has previously 
been implicated in human cancer war-
rants particular emphasis. This sug-
gests that approaches like these can 
still yield a treasure trove of new genes 
relevant to cancer. Such genes, by vir-
tue of their in vivo validation and estab-
lished role in human cancer, have great 
value as potential drug targets.
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Mutations in LRP5, a coreceptor for Wnt proteins, cause the disease osteoporosis pseudoglioma. 
A new study by Yadav et al. (2008) now challenges the view that LRP5 controls bone mass through 
Wnt signaling in bone and argues instead that LRP5 regulates bone mass indirectly through its 
effects on serotonin synthesis in the gut.Wnt signaling has been intensively stud-
ied by bone biologists since the discov-
ery that loss-of-function mutations in 
low-density lipoprotein receptor-related 
protein 5 (LRP5), a coreceptor for Wnt 
ligands, underlie the hereditary disease 
osteoporosis pseudoglioma (OPPG) 
(Gong et al., 2001). Conversely, gain-
of-function mutations in LRP5 cause 
high bone mass syndromes in humans 
(Boyden et al., 2002; Little et al., 2002). 
Additional studies have implicated Wnt 
signaling in the production and func-
tion of osteoblasts (bone-forming cells) 
including genetic deletion of β-catenin, a 
central component of the canonical Wnt 
pathway, which results in a complete 
lack of mature osteoblasts in the mouse 
(Day et al., 2005; Hill et al., 2005; Hu et 
al., 2005; Rodda and McMahon, 2006). 
Therefore, a current prevailing model 
posits that canonical Wnt signaling via 
the cell-surface molecule LRP5, or the 
related protein LRP6, directly controls osteoblast formation or function. How-
ever, direct genetic evidence linking 
the role of LRP5 in bone formation with 
canonical Wnt signaling in osteoblasts 
has been lacking. In this issue of Cell, 
Yadav et al. (2008) provide compelling 
evidence that Lrp5 indirectly enhances 
bone formation through inhibition of 
serotonin production in the mouse duo-
denum, thereby revealing the existence 
of a gut-to-bone endocrine axis.
Prior work provided hints that canoni-
cal Wnt signaling in bone might not be 
sufficient by itself to explain the effects 
of LRP5 mutations on bone mass. 
Mice lacking Lrp5 in all cells, similar to 
patients with OPPG, exhibit low bone 
mass during early postnatal life, owing 
to decreased osteoblast proliferation 
and function (Kato et al., 2002). Yet, mice 
lacking β-catenin specifically in more 
mature osteoblasts due to expression 
of Cre-recombinase under the control of 
the collagen I promoter (ColI-Cre) do not Cell 135, Ndisplay a clear osteoblast phenotype. 
These mice do show increased formation 
of osteoclasts (bone-degrading cells) 
secondary to a decrease in the osteo-
blast-derived anti-osteoclastogenic fac-
tor osteoprotegerin (OPG) (Glass et al., 
2005). This discrepancy suggested that 
the osteoblast defect caused by Lrp5 
deficiency may occur at an earlier stage 
of osteoblast development than is tar-
geted by the ColI-Cre transgene. Alter-
natively, Lrp5 may control bone forma-
tion either independently of β-catenin 
or not through direct effects on osteo-
blasts, or both.
To shed light on the molecular mech-
anism through which LRP5 controls 
bone formation, Yadav et al. (2008) per-
formed microarray experiments with 
RNA extracted from wild-type and Lrp5-
deficient mouse bones. They discovered 
that the most highly expressed gene in 
mutant bone tissue compared with wild-
type was Tph1, which encodes trypto-ovember 28, 2008 ©2008 Elsevier Inc. 795
phan hydroxylase, a rate-limiting enzyme 
for serotonin synthesis in the enterochro-
maffin cells of the duodenum. Indeed, 
Tph1 mRNA was also greatly upregulated 
in the duodenum, and serum serotonin 
levels were markedly increased in Lrp5-
deficient mice. Because serotonin has 
been implicated in regulating the accrual 
of bone mass (Warden et al., 2005), this 
finding raised the possibility that Lrp5 
may exert its function on bone through 
gut-derived serotonin. The authors vig-
orously tested this hypothesis.
The authors first show that Lrp5 
functions through the gut, instead of 
bone, to promote bone mass accrual. 
Gut-specific deletion of Lrp5 (using a 
Villin-Cre transgene) recapitulates the 
same low bone mass phenotype as the 
Lrp5 null mice, which is characterized 
by reduced mineral apposition rate 
and decreased osteoblast prolifera-
tion concurrent with reduction of the 
cyclins D1, D2, and E1. In contrast, 
osteoblast-specific deletion of Lrp5 
does not cause a similar osteoblast 
defect. In converse experiments, gut-
specific expression of an Lrp5 allele 
harboring a mutation that leads to high 
bone mass causes a high bone mass 
phenotype, whereas expression of the 
same allele in osteoblasts fails to do 
so. Importantly, mice with gut-specific 
deletion of Lrp5 exhibit an increased 
level of serum serotonin, whereas the 
gut-specific expression of a high bone 
mass Lrp5 allele causes a decrease in 
serum serotonin levels. Similar genetic 
manipulations in osteoblasts, however, 
do not alter the serum serotonin levels. 
Remarkably, the low bone mass pheno-
type in Lrp5-deficient mice is reversed 
upon lowering of serotonin levels by 
either a diet low in tryptophan or an 
inhibitor of serotonin synthesis. These 
results therefore demonstrate that Lrp5 
functions predominantly in the gut, but 
not in osteoblasts, to stimulate osteo-
blast proliferation. Furthermore, gut-
derived serotonin may be a key media-
tor of Lrp5 function.
Indeed, gut-derived serotonin nega-
tively controls bone mass. Gut-specific 
deletion of Tph1 drastically reduces 
serum serotonin levels and also increases 
bone mass. Conversely, osteoblast-spe-
cific deletion of Tph1 has no effect on 
bone mass, indicating that Tph1, although 796 Cell 135, November 28, 2008 ©2008 Elsreduced in the bones of Lrp5-deficient 
mice, does not appear to play a direct role 
in bone formation. Furthermore, circulat-
ing serotonin appears to inhibit bone for-
mation by signaling specifically through 
the serotonin receptor HTR1B in osteo-
blasts; HTR1B signaling in turn inhibits 
both expression and phosphorylation-
dependent activation of the transcription 
factor CREB, which itself is necessary 
for optimal expression of cyclin D1 and 
presumably for normal osteoblast prolif-
eration. Interestingly, the mice that lack 
expression of Tph1 in the gut appear to be 
resistant to bone loss due to ovariectomy, 
even though bone resorption is induced 
in these mice.
The authors also provide evidence that 
Lrp5 and serotonin function genetically in 
the same pathway. In particular, removal 
of either one Tph1 allele from the gut or 
one Htr1b allele globally normalizes bone 
mass in the Lrp5-deficient mice.
The study does not rule out the pos-
sibility that Lrp5 may directly regulate 
osteoblast differentiation in bone post-
natally. However, the study does restrict 
any such potential regulation to a devel-
opmental stage prior to that targeted by 
the ColI-Cre transgene. Moreover, such 
a potential role does not appear to con-
tribute significantly to the bone parame-
ters assayed in this study and therefore, 
by inference, may not be the main cause 
of the bone defect in OPPG patients. A 
model in which serotonin has a primary 
role is also consistent with the obser-
vation that circulating serotonin was 
significantly elevated in several OPPG 
patients.
The molecular mechanism through 
which Lrp5 inhibits Tph1, and conse-
quently decreases serotonin expres-
sion in the enterochromaffin cells, is 
not understood. Although Wnt signal-
ing is known to regulate cell fates in 
the intestine, Lrp5 does not appear to 
alter the identity and organization of 
cell types in the duodenum. Lrp5 could 
function through Wnt signaling to reg-
ulate Tph1 expression, although the 
authors do not observe a genetic inter-
action between Lrp5 and β-catenin in 
bone mass regulation. Alternatively, 
Lrp5 may function in a yet unknown 
context to inhibit Tph1 expression. 
Finally, Lrp5 may have other media-
tors in the intestine besides Tph1 and evier Inc.serotonin. This possibility is consistent 
with the observation that the effect of 
gut-specific deletion of Tph1 on bone is 
less severe than the phenotype result-
ing from the gut-specific expression of 
the high bone mass allele of Lrp5, even 
though the level of serum serotonin 
in the Tph1-deficient mice is mark-
edly lower than that found in the Lrp5 
mouse model.
The discovery of LRP5 as the dis-
ease gene in OPPG patients ushered in 
a new era of studying Wnt signaling in 
bone, which in turn has led to substan-
tial evidence that this pathway exerts 
direct regulation on the osteoblast lin-
eage. The new study by Yadav et al. 
now calls into question the physiologi-
cal relevance of direct bone Wnt-Lrp5 
signaling in the pathogenesis of OPPG. 
One cannot help asking, have we once 
again been studying the right molecule 
for the wrong reason?
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